| Literature DB >> 31094921 |
Cheng-Han Lee1, Yu-Chien Kao2, Wan-Ru Lee3, Yi-Wen Hsiao4, Tzu-Pin Lu4, Chia-Ying Chu5, Yi-Jia Lin6, Hsuan-Ying Huang7, Tsung-Han Hsieh8, Yun-Ru Liu8, Cher-Wei Liang9, Tom Wei-Wu Chen10, Stephen Yip11, Amy Lum11, Kuan-Ting Kuo3, Yung-Ming Jeng3, Shih-Chen Yu7, Yung-Chuan Chung3, Jen-Chieh Lee3.
Abstract
Uterine mesenchymal tumors are genetically heterogenous; those with uniform cytomorphology, best exemplified by endometrial stromal tumors, often contain various fusion genes. Novel fusions involving ESR1 and GREB1, key factors in sex hormone pathways, have been implicated in rare uterine mesenchymal tumors. Particularly, the fusions between 5'-ESR1/GREB1 and 3'-NCOA2/NCOA3 were recently identified in 4 uterine tumors resembling ovarian sex-cord tumor (UTROSCT). By RNA sequencing, pathology review, and FISH screening, we identified 4 uterine sarcomas harboring rearranged GREB1, including GREB1-NCOA2 and the novel GREB1-NR4A3, GREB1-SS18, and GREB1-NCOA1, validated by RT-PCR and/or FISH. They occurred in the myometrium of postmenopausal women and were pathologically similar despite minor differences. Tumor cells were generally uniform and epithelioid, with vesicular nuclei and distinct to prominent nucleoli. Growth patterns included solid sheets, trabeculae/cords, nests, and fascicles. Only 1 tumor showed small foci of definitive sex-cord components featuring well-formed tubules, retiform structures, Leydig-like cells, and lipid-laden cells and exhibiting convincing immunoreactivity to sex-cord markers (calretinin, α-inhibin, and Melan-A). In contrast, all the 4 classic UTROSCT we collected occurred in premenopausal patients, consisted predominantly of unequivocal sex-cord elements, prominently expressed multiple sex-cord markers, and harbored ESR1-NCOA3 fusion. Combined with previously reported cases, GREB1-rearranged tumors involved significantly older women (P=0.001), tended to be larger and more mitotically active, showed more variable and often inconspicuous sex-cord differentiation, and appeared to behave more aggressively than ESR1-rearranged UTROSCT. Therefore, these 2 groups of tumors might deserve separate consideration, despite some overlapping features and the possibility of belonging to the same disease spectrum.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31094921 DOI: 10.1097/PAS.0000000000001265
Source DB: PubMed Journal: Am J Surg Pathol ISSN: 0147-5185 Impact factor: 6.394